GlassScriptPhysician profile
Garrett N Bennett
NPI 1336135946
$2,236.42
in general payments reported to CMS, 2019-2025
26 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $116 · 2020: $217 · 2021: $156 · 2022: $393 · 2023: $395 · 2024: $497 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,354.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,353.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $457.63 | 2019-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $359.21 | 2019-2025 | Farxiga, Airsupra |
| Dexcom, INC. | $237.55 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $206.67 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $158.13 | 2020-2025 | Jardiance, Ofev |
| Abbvie INC. | $132.73 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $85.63 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $74.20 | 2024-2025 | Daybue |
| Takeda Pharmaceuticals U.S.A., INC. | $64.40 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $51.67 | 2023-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $51.48 | 2021-2023 | Trelegy Ellipta |
| Bayer Healthcare Pharmaceuticals INC. | $47.70 | 2022-2024 | |
| Vifor Pharma, INC. | $42.85 | 2022-2023 | Veltassa |
| Astellas Pharma US INC | $36.48 | 2024 | Veozah |
| Amgen INC. | $30.27 | 2025 | Repatha, Otezla |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $27.83 | 2025 | Auvelity |
| Averitas Pharma INC. | $24.34 | 2025 | Qutenza |
| Nestle Healthcare Nutrition INC. | $20.84 | 2023 | |
| Merck Sharp & Dohme LLC | $19.03 | 2023 | Verquvo, Belsomra |
| Abbott Laboratories | $17.77 | 2022 | |
| Portola Pharmaceuticals, LLC | $17.29 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $15.87 | 2024 | Nuedexta |
| Melinta Therapeutics, LLC | $15.47 | 2022 | |
| Ibsa Pharma INC. | $15.26 | 2025 | Tirosint, Flector, Licart |
| Paratek Pharmaceuticals, INC. | $15.07 | 2025 | Nuzyra |
| Pfizer INC. | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Garrett Bennett listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.